Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Active Ankylosing Spondylitis

In brief

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.

Key facts

Study ID

NCT07172360

Run by

Jiangsu vcare pharmaceutical technology co., LTD

People needed

420

Starts

2025-12-26

Expected to finish

2027-08-30

Last updated by the study team

2026-01-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
• The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
• The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis

You may not qualify if…

• Those who may be allergic to VC005, similar drugs or their excipients.
• Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
• Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.